The nivolumab cohort had higher proportions of patients with Child‐Pugh B9 cirrhosis, hepatic encephalopathy, ECOG performance status ≥2, macrovascular invasion, extrahepatic spread, CVA or MI in the prior 5 years, VTE in the prior 5 years, variceal bleeding in the prior 5 years, treatment at more complex VA medical centers, and higher median AFP compared to the sorafenib cohort (Table 1). Here, AFP is linked to Cirrhosis.